CompletedPhase 1NCT01522547
Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease
Studying Genetic hemoglobinopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Celgene
- Principal Investigator
- Robert Knight, MD, MD, MPHCelgene
- Intervention
- pomalidomide(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2007 – 2013
Study locations (1)
- Karmanos Cancer Institute, Detroit, Michigan, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01522547 on ClinicalTrials.govOther trials for Genetic hemoglobinopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07087262A Phase I Study of SNH-119014 in Healthy VolunteersScinnoHub Pharmaceutical Co., Ltd.
- RECRUITINGNANCT06886477Sickle Cell, Pain and Mediterranean DietUniversity of Illinois at Chicago
- RECRUITINGPHASE1, PHASE2NCT06144749A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)Hillhurst Biopharmaceuticals, Inc.
- RECRUITINGNANCT07064941Effect of Exercise on Body Composition and Bone Health in Patients With ThalassemiaUniversity of California, San Francisco
- ACTIVE NOT RECRUITINGNANCT06800495Development of THALEA Kit and Its Impact on Knowledge, Attitude, and Intention for Premarital Thalassemia ScreeningUniversiti Teknologi Mara
- ENROLLING BY INVITATIONNCT07003256Observational Study: Romiplostim for Platelet Recovery in Haploidentical HSCTHaikou Affiliated Hospital of Central South University Xiangya School of Medicine
- RECRUITINGPHASE1, PHASE2NCT06481306A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell DiseaseBristol-Myers Squibb
- RECRUITINGNANCT06031714Fetal Cell Receptors RepertoireAssistance Publique - Hôpitaux de Paris